Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic User Fee Talks Reach 'Final Wording' But Still Not Done

Executive Summary

FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.

You may also be interested in...



GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began

Generic drug reviews during the first year of formal review goals cost 70% more than during GDUFA's inaugural year.

ANDA User Fees Offer Sponsor Relief, But More Facility Pain

Final GDUFA I application fees decrease amid expected boost in submissions, while facility fees will increase for the fourth time in five years.

Will PDUFA VI Fee Structure Changes Slow Revenue Growth?

User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS118881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel